Terry Furlong

1.3k citations

18 papers · 843 indexed · h-index 13

Transplantation top 2%
- Renal Transplantation Outcomes and Treatments 5
Hematology top 1%
- Hematopoietic Stem Cell Transplantation 16
- Acute Myeloid Leukemia Research 4
Immunology top 10%
Genetics top 10%
- Chronic Lymphocytic Leukemia Research 2
- Mesenchymal stem cell research 2
Oncology
- Polyomavirus and related diseases 4
Public Health, Environmental and Occupational Health
- Acute Lymphoblastic Leukemia research 6
Pediatrics, Perinatology and Child Health
- Childhood Cancer Survivors' Quality of Life 3

Co-authors: Paul J. Martin Marco Mielcarek Rainer Storb Richard A. Nash Frederick R. Appelbaum H. Joachim Deeg Barry E. Storer Paul V. O’Donnell
Cited by: Transplantation Hematology Immunology
Journals: Journal of Clinical Oncology (2 papers)Blood (3 papers)PLoS ONE (1 paper)
Partner nations: United States South Africa Sweden

In The Last Decade

Terry Furlong

17 papers receiving 835 citations

Peers

Countries citing papers authored by Terry Furlong

Since Specialization

Citations

This map shows the geographic impact of Terry Furlong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Terry Furlong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Terry Furlong more than expected).

Fields of papers citing papers by Terry Furlong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Terry Furlong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Terry Furlong. The network helps show where Terry Furlong may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Terry Furlong, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Terry Furlong Line = papers co-authored together Terry Furlong links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work
1	Impact of Donor Statin Treatment on Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation Transplantation and Cellular Therapy ·Nahid Rashid,Ted Gooley,Terry Furlong,Stephanie J. Lee,Paul J. Martin,Rainer Storb,Marco Mielcarek	2023	1
2	Pilot study of lithium to restore intestinal barrier function in severe graft-versus-host disease PLoS ONE ·Gideon Steinbach,David M. Hockenbery,Gerwin Huls,Terry Furlong,David Myerson,Keith R. Loeb,Jesse R. Fann,C Castilla-Llorente,George B. McDonald,Paul J. Martin	2017	13
3	Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation Blood ·Marco Mielcarek,Terry Furlong,Paul V. O’Donnell,Barry E. Storer,Jeannine S. McCune,Rainer Storb,Paul A. Carpenter,Mary E.D. Flowers,Frederick R. Appelbaum,Paul J. Martin	2016	143
4	Multi-Institutional Study of Post-Transplantation Cyclophosphamide As Single-Agent Graft-Versus-Host Disease Prophylaxis After Allogeneic Bone Marrow Transplantation Using Myeloablative Busulfan and Fludarabine Conditioning Journal of Clinical Oncology ·Christopher G. Kanakry,Paul V. O’Donnell,Terry Furlong,Marcos J. de Lima,Wei Wei,Marta Medeot,Marco Mielcarek,Richard E. Champlin,Richard J. Jones,Peter F. Thall,Börje S. Andersson,Leo Luznik	2014	170
5	Multi-institutional study of allogeneic bone marrow transplantation using myeloablative busulfan (Bu)/fludarabine (Flu) conditioning and short-course, single-agent graft-versus-host disease (GVHD) prophylaxis with high-dose, post-transplantation cyclophosphamide (PTCy). Journal of Clinical Oncology ·Christopher G. Kanakry,Paul V. O’Donnell,Marcos J.G. De Lima,Wei Wei,Terry Furlong,Marta Medeot,Richard J. Jones,Peter F. Thall,Börje S. Andersson,Leo Luznik	2013	0
6	Post-Transplantation Cyclophosphamide Following Busulfan and Fludarabine Myeloablative Conditioning Prevents Severe Acute and Chronic Graft-Versus-Host Disease and Minimizes Duration Of Immunosuppression: Results Of a Multi-Institutional Trial In Patients With High-Risk Hematologic Malignancies Blood ·Christopher G. Kanakry,Paul V. O’Donnell,Terry Furlong,Marcos J. de Lima,Wei Wei,Marta Medeot,Marco Mielcarek,Richard E. Champlin,Richard J. Jones,Peter F. Thall,Börje S. Andersson,Leo Luznik	2013	1
7	Evaluation of Oral Beclomethasone Dipropionate for Prevention of Acute Graft-versus-Host Disease Biology of Blood and Marrow Transplantation ·Paul J. Martin,Terry Furlong,Scott D. Rowley,Steven A. Pergam,Michele Lloid,Mark M. Schubert,Kevin Horgan,Barry E. Storer	2011	16
8	A pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipients Cancer Chemotherapy and Pharmacology ·Jeannine S. McCune,Erica L. Woodahl,Terry Furlong,Barry E. Storer,Joanne Wang,Shelly Heimfeld,H. Joachim Deeg,Paul V. O’Donnell	2011	16
9	A Retrospective Comparison of Tacrolimus versus Cyclosporine with Methotrexate for Immunosuppression after Allogeneic Hematopoietic Cell Transplantation with Mobilized Blood Cells Biology of Blood and Marrow Transplantation ·Yoshihiro Inamoto,Mary E.D. Flowers,Frederick R. Appelbaum,Paul A. Carpenter,H. Joachim Deeg,Terry Furlong,Hans-Peter Kiem,Marco Mielcarek,Richard A. Nash,Rainer Storb,Robert P. Witherspoon,Barry E. Storer,Paul J. Martin	2011	27
10	Longitudinal Assessment of Morbidity and Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation: Retrospective Analysis of a Multicenter Phase III Study Biology of Blood and Marrow Transplantation ·Fabrizio Carnevale‐Schianca,Wendy M. Leisenring,Paul J. Martin,Terry Furlong,Gary Schoch,Claudio Anasetti,Frederick R. Appelbaum,Paul A. Carpenter,H. Joachim Deeg,Hans‐Peter Kiem,Rainer Storb,George B. McDonald,Richard A. Nash	2009	13
11	Sirolimus in Combination with Cyclosporine or Tacrolimus Plus Methotrexate for Prevention of Graft-versus-Host Disease following Hematopoietic Cell Transplantation from Unrelated Donors Biology of Blood and Marrow Transplantation ·Terry Furlong,Hans‐Peter Kiem,Frederick R. Appelbaum,Paul A. Carpenter,H. Joachim Deeg,K Doney,Mary E.D. Flowers,Marco Mielcarek,Richard A. Nash,Rainer Storb,Paul J. Martin	2008	39
12	Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes Blood ·Marco Mielcarek,Barry E. Storer,Michael Boeckh,Paul A. Carpenter,George B. McDonald,H. Joachim Deeg,Richard A. Nash,Mary E.D. Flowers,K Doney,Stephanie J. Lee,Kieren A. Marr,Terry Furlong,Rainer Storb,Frederick R. Appelbaum,Paul J. Martin	2008	88
13	A Phase I/II Study of Mycophenolate Mofetil in Combination with Cyclosporine for Prophylaxis of Acute Graft-versus-Host Disease after Myeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation Biology of Blood and Marrow Transplantation ·Richard A. Nash,Laura Johnston,Pablo Parker,Jeannine S. McCune,Barry E. Storer,John T. Slattery,Terry Furlong,Claudio Anasetti,Frederick R. Appelbaum,Michele Lloid,H. Joachim Deeg,Hans‐Peter Kiem,Paul J. Martin,Mark M. Schubert,Robert P. Witherspoon,Stephen J. Forman,Karl G. Blume,Rainer Storb	2005	95
14	Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease Biology of Blood and Marrow Transplantation ·Terry Furlong,Wendy M. Leisenring,Rainer Storb,Claudio Anasetti,Frederick R. Appelbaum,Paul A. Carpenter,H. Joachim Deeg,K Doney,Hans‐Peter Kiem,Richard A. Nash,Jean E. Sanders,Robert P. Witherspoon,Dianne Thompson,Paul J. Martin	2002	45
15	The English Teacher Recruitment and Retention Project Viv Ellis,Terry Furlong,G. A. A. Grant	2002	1
16	SIROLIMUS (RAPAMYCIN) FOR THE TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE1 Transplantation ·Ana Benito,Terry Furlong,Paul J. Martin,Claudio Anasetti,Frederick R. Appelbaum,Kris Doney,Richard A. Nash,Thalia Papayannopoulou,R Storb,Keith Sullivan,Robert Witherspoon,H. Joachim Deeg	2001	139
17	Key stage 3 national strategy : an evaluation of the English and mathematics strategies - interim report Research Portal (King's College London) ·Terry Furlong,Hamsa Venkatakrishnan,Margaret Brown	2001	1
18	Changing from cyclosporine to tacrolimus as salvage therapy for chronic graft-versus-host disease Biology of Blood and Marrow Transplantation ·Fabrizio Carnevale‐Schianca,Paul J. Martin,Keith M. Sullivan,Mary E.D. Flowers,Ted Gooley,Claudio Anasetti,Joachim Deeg,Terry Furlong,Peter A. McSweeney,Rainer Storb,Richard A. Nash	2000	35

About Terry Furlong

Terry Furlong is a scholar working on Transplantation, Hematology and Genetics, having authored 18 papers that have together received 843 indexed citations. Recurring topics across this work include Hematopoietic Stem Cell Transplantation (16 papers), Acute Lymphoblastic Leukemia research (6 papers), Renal Transplantation Outcomes and Treatments (5 papers), Acute Myeloid Leukemia Research (4 papers), Polyomavirus and related diseases (4 papers), Childhood Cancer Survivors' Quality of Life (3 papers), Chronic Lymphocytic Leukemia Research (2 papers) and Mesenchymal stem cell research (2 papers). The work is most often cited by research in Transplantation (220 citations), Hematology (746 citations) and Immunology (329 citations). Terry Furlong has collaborated with scholars based in United States, South Africa and Sweden. Frequent co-authors include Paul J. Martin, Marco Mielcarek, Rainer Storb, Richard A. Nash, Frederick R. Appelbaum, H. Joachim Deeg, Barry E. Storer, Paul V. O’Donnell, Paul A. Carpenter and Mary E.D. Flowers. Their work appears in journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact